Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
ATRC-101: A first-in-class engineered fully human monoclonal antibody that targets a tumor-restricted ribonucleoprotein complex Del-alco, J., Emerling, D., Manning-Bog, A., Baia, G., Lippow, S., Scholz, A., Zhu, Y., Cavet, G., Volkmuth, W., Dhawan, I., Benjamin, J., Robinson, W., Serafini, T., Greenberg, N. BMC. 2019
View details for Web of Science ID 000496473200274